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1  | INTRODUC TION
Subarachnoid hemorrhage (SAH) has a reported incidence between 
10 and 15 people per 100 000 in the United States.1,2 Despite sig‐
nificant improvements in treatment modalities and critical care man‐
agement, SAH is associated with significant morbidity, mortality, and 
socioeconomic impact. This is not only as a result of the hemorrhagic 
event, but further related to the sequelae of the irritating blood 
by‐products that can lead to cerebral vasospasm and delayed cere‐
bral ischemia (DCI) and can impair the circulation of cerebrospinal 
fluid (CSF) with resultant hydrocephalus. The absence of prevention 
strategies or efficacious therapy of cerebral vasospasm and DCI has 
resulted in rigorous research efforts. A multitude of animal models 
have been designed to address the complex pathogenesis of cerebral 
vasospasm. The preclinical animal studies have led to multiple clinical 
trials evaluating different potential therapeutic strategies. Available 
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Aneurysmal subarachnoid hemorrhage (aSAH) continues to be associated with sig‐
nificant morbidity and mortality despite advances in care and aneurysm treatment 
strategies. Cerebral vasospasm continues to be a major source of clinical worsening 
in patients. We intended to review the clinical and experimental aspects of aSAH and 
identify strategies that are being evaluated for the treatment of vasospasm. A litera‐
ture review on aSAH and cerebral vasospasm was performed. Available treatments 
for aSAH continue to expand as research continues to identify new therapeutic tar‐
gets. Oral nimodipine is the primary medication used in practice given its neuro‐
protective properties. Transluminal balloon angioplasty is widely utilized in patients 
with symptomatic vasospasm and ischemia. Prophylactic “triple‐H” therapy, clazos‐
entan, and intraarterial papaverine have fallen out of practice. Trials have not shown 
strong evidence supporting magnesium or statins. Other calcium channel blockers, 
milrinone, tirilazad, fasudil, cilostazol, albumin, eicosapentaenoic acid, erythropoi‐
etin, corticosteroids, minocycline, deferoxamine, intrathecal thrombolytics, need to 
be further investigated. Many of the current experimental drugs may have signifi‐
cant roles in the treatment algorithm, and further clinical trials are needed. There is 
growing evidence supporting that early brain injury in aSAH may lead to significant 
morbidity and mortality, and this needs to be explored further.
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treatments for aneurysmal SAH continue to expand as research con‐
tinues to identify new therapeutic targets. We intended to review 
the clinical and experimental aspects of aSAH and identify strategies 
that are being evaluated for the treatment of cerebral vasospasm.
2  | METHODS
A literature review on aSAH was performed using PubMed. The fol‐
lowing search terms were used: aneurysmal subarachnoid hemorrhage 
(aSAH), cerebral vasospasm, DCI, hydrocephalus, triple‐H therapy, ni‐
modipine, magnesium, milrinone, statins, endothelin receptor antago‐
nists, tirilazad, fasudil, cilostazol, albumin, corticosteroids, minocycline, 
deferoxamine, intrathecal therapy, intraventricular therapy, intraaterial 
therapy, angioplasty, and animal models of SAH. We evaluated studies 
in English that investigated interventions for managing aSAH.
3  | RESULTS
3.1 | Presentation and diagnosis of SAH
Most SAHs are caused by a ruptured intracranial aneurysm and are 
referred to as aSAH. The prevalence of intracranial aneurysms is 
about 3%.3
The primary symptom of aSAH is a sudden, severe headache 
classically described as the "worst headache of life," and may be 
accompanied by a brief loss of consciousness, nausea or vomiting, 
meningismus, and seizures.4 At least 10%‐15% of patients with aSAH 
die before reaching the hospital. Noncontrast head computed to‐
mography (CT) scan is the mainstay of diagnosis of SAH.5 Cerebral 
angiography is then pursued to identify the etiology of SAH. Both 
CT angiography (CTA) and magnetic resonance angiography (MRA) 
can identify aneurysms 3‐5 mm or larger with a high degree of sensi‐
tivity,6 but digital subtraction cerebral angiography remains the gold 
standard test to identify the etiology of SAH. Lumbar puncture can 
be considered if there is a strong suspicion of SAH despite a normal 
head CT. A patient presenting with aSAH is admitted to an intensive 
care unit for hemodynamic and neurological monitoring, and com‐
monly ventriculostomy placement for drainage of CSF and recording 
of intracranial pressure. This is followed by definitive treatment of 
the ruptured aneurysm or pathology causing the SAH.5
3.2 | Treatment of cerebral aneurysms
Treatment of cerebral aneurysms falls primarily under two treatment 
categories: surgical clipping and endovascular treatment.7,8 Surgical 
management of cerebral aneurysms typically consists of clip place‐
ment across the neck of the aneurysm. It has been proven to be an 
effective and safe procedure and was long the most practiced tech‐
nique for treatment of intracranial aneurysms. Endovascular therapy 
for cerebral aneurysms was introduced in the early 1990s with the 
advent of the Guglielmi platinum detachable coils.9 Access is typi‐
cally obtained through the femoral artery, and with the assistance of 
catheters and wires, the aneurysm is reached and coils are deployed. 
A local thrombus then forms around the coils, obliterating the aneu‐
rysmal sac. More recent techniques have evolved to target complex 
aneurysms. These include stent‐assisted coiling,10 balloon‐assisted 
coiling,11 flow diverters,12 and embolic agents.13
Multiple factors affect the approach utilized to treat a cerebral 
aneurysm, most notably aneurysm location, size, and neck size. 
Endovascular treatment is often the preferred technique for pos‐
terior circulation aneurysms and ruptured aneurysms in elderly 
patients (>70 years of age) given higher surgical risks.14 In contrast, 
aneurysms in the middle cerebral artery, ruptured aneurysms with 
large intraparenchymal hematomas, are most commonly approached 
surgically.5 Combined endovascular and surgical techniques may be 
required with some very large or complex aneurysms.
The ISAT, a multicenter randomized trial comparing microsurgical 
and endovascular treatment, randomized 2143 patients with aSAH.7 
One‐year outcomes demonstrated a reduction in death and disabil‐
ity from 31% in the microsurgery group to 24% in the endovascular 
arm (relative risk reduction of 24%). The risk of epilepsy and signifi‐
cant cognitive decline was also reduced in the endovascular group. 
Rebleeding occurred more commonly in the endovascular treatment 
group (2.9% after endovascular repair vs 0.9% after open surgery). 
The rate of complete aneurysm occlusion was lower with coiling 
(58% compared with 81% of clipped aneurysms). Due to lower mor‐
bidity, endovascular approaches are gaining more and more popular‐
ity. Both microsurgical and endovascular approaches are evaluated 
on a case‐to‐case basis.
A multitude of secondary events may arise after aneurysmal rup‐
ture, some even after securing the aneurysm, and may contribute to 
brain injury and affect clinical outcomes. (Table 1).
3.3 | Hydrocephalus
Hydrocephalus after aSAH is thought to be caused by obstruction of 
CSF flow by blood products or adhesions, or by a reduction of CSF 
absorption at the arachnoid granulations, or by an increase in CSF 
secretion.15 The reported rate of hydrocephalus after aSAH ranges 
from 15% to 87% on CT imaging.5 Acute hydrocephalus associated 
with aSAH is usually managed by external ventricular drainage or 
lumbar drainage. Acute CSF diversion for patients who develop hy‐
drocephalus is shown to improve neurological outcomes.16‐18
Chronic hydrocephalus associated with aSAH is usually treated 
with a shunt placement for continuous CSF drainage, typically a 
ventriculoperitoneal shunt.19 Not all patients with aSAH‐associated 
acute hydrocephalus develop shunt‐dependent chronic hydroceph‐
alus. Besides CSF diversion, there are no other medical or surgi‐
cal interventions that are proven to reduce the rate of post‐aSAH 
hydrocephalus.
3.4 | Rebleeding
Treatment of the ruptured aneurysm should be performed as early 
as possible to reduce the rate of rebleeding after aSAH. Rebleeding 
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occurs in 7%‐23% of patients and is a major predictor of poor out‐
come in patients with aSAH.20‐22 Most studies have found that the 
risk of rebleeding is highest in the first 24 hours after aSAH.
Patients are at substantial risk of rebleeding early after presenta‐
tion if the aneurysm is unsecured, with reported rates of rebleeding 
ranging from 4% to 13.6% within the first 24 hours. The risk is at 
its highest within six hours of the initial hemorrhage. The risk of re‐
bleeding drops later to 1%‐2% each day in the first month following 
the hemorrhage.5,21,23,24
The mortality associated with rebleeding is reported to be as 
high as 70%.25 The main factors that increase the risk of rebleeding 
are longer time to aneurysm treatment, worse neurological condi‐
tion on presentation, larger aneurysm size, and persistently elevated 
systolic blood pressure.21,24 Hypertension should be controlled after 
aSAH and until aneurysm treatment. A decrease in systolic blood 
pressure to <160 mm Hg is reasonable.5
Antifibrinolytic therapy has been shown to reduce the incidence 
of aneurysm rebleeding when there is a delay in aneurysm oblitera‐
tion. This may increase the risk of deep venous thrombosis.26 For pa‐
tients with an unavoidable delay in obliteration of aneurysm, and no 
contraindications, short‐term (<72 hours) therapy with tranexamic 
acid or aminocaproic acid could be attempted to decrease the risk of 
early aneurysm rebleeding.5
3.5 | Vasospasm
Cerebral vasospasm after aSAH is defined as narrowing of the 
large and medium‐sized intracranial arteries. It represents one 
of the major causes of morbidity and mortality in patients with 
aSAH who reach the hospital and are undergoing medical care. 
The risk of vasospasm typically begins around day 3 and peaks 
around days 7‐10. The risk typically resolves 21 days after the 
bleed.5 Angiographic vasospasm is seen in 30%‐70% of patients 
with aSAH, and clinical or symptomatic vasospasm is seen in 
20%‐30% of patients.27,28 Cerebral vasospasm is a clinical diagno‐
sis, and radiographic studies are utilized to support the diagnosis. 
The gold standard for detecting cerebral vasospasm remains digi‐
tal subtraction angiography, and it has the advantage of being both 
a diagnostic and therapeutic tool. CTA is often employed as well 
for the detection of cerebral vasospasm, as it can provide a quick 
tool for diagnosis and monitoring of vasospasm. CT perfusion is 
another tool that can be useful to assess for cerebral ischemia and 
infarction as a result of vasospasm.29 Transcranial Doppler sonog‐
raphy (TCD) is widely used for detecting and monitoring vasos‐
pasm in aSAH in the clinical setting. It is often used daily in the 
first 2 weeks after aSAH and can follow the temporal course of 
vasospasm. TCD is highly operator‐dependent, and data obtained 
from TCD should always be correlated with how the patient is 
doing clinically.30
Cerebral vasospasm can lead to regional cerebral hypoperfusion 
and DCI, which constitutes a major cause of death and disability in 
patients with aSAH. DCI typically causes neurological deterioration 
or new focal neurological deficits.
Vasospasm leads to DCI in approximately 20%‐30% of patients 
with aSAH.31‐33
Though the exact mechanism of how vasospasm occurs is still 
not completely elucidated, there are many proposed mechanisms, 
with cerebral vasospasm likely being a multifactorial pathology. 
The major proposed pathways contributing to vasospasm include 
the following: endothelial damage and formation of microthrombi, 
smooth muscle contraction from lysis of subarachnoid blood clots 
and blood degradation products and hemoglobin released into the 
subarachnoid space, decreased nitric oxide production leading to 
prolonged vasoconstriction, increased production and release of the 
potent vasoconstrictor endothelin‐1, cortical spreading depolariza‐
tion, inflammation‐mediated oxidative stress and free radical dam‐
age to smooth muscle cells, and upregulation of apoptosis pathways 
following aSAH (Table 2).34‐39
As a consequence of the significant neurological morbidity or 
mortality of cerebral vasospasm and DCI, research has heavily fo‐
cused on understanding the physiological mechanisms behind these 
events and developing effective preventive and therapeutic mea‐
sures (Table 3). The cornerstone of vasospasm treatment continues 
to be focused on prevention given risk for worse clinical outcomes in 
patients who develop this condition.
3.6 | Therapies investigated in managing vasospasm
3.6.1 | Hyperdynamic therapy
Hyperdynamic therapy, including induced hypertension, hyperv‐
olemia, and hemodilution, referred to as "triple‐H" therapy, has been 
TA B L E  1   Events/complications encountered in patients with aSAH after presentation and on follow‐up
Early Late Chronic
Rebleeding Cerebral vasospasm Chronic hydrocephalus that may require placement of a shunt
Acute hydrocephalus Delayed cerebral ischemia Behavior, personality, and memory changes
Seizures Pituitary dysfunction Need for further retreatment for recurrent or residual aneurysm
Cardio‐pulmonary issues and 
stress‐induced cardiomyopathy
Infection related to surgery or 
ventriculostomy.
 
Sodium and electrolyte 
abnormalities
  
Abbreviation: aSAH, aneurysmal subarachnoid hemorrhage.
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used as a method to prevent and treat cerebral vasospasm.40‐42 The 
goal of this technique is to raise the mean arterial pressure and in‐
crease cerebral perfusion. It was one of the mainstays of vasospasm 
management and prevention. However, studies failed to show ben‐
efit of prophylactic triple‐H therapy and highlighted some notable 
risks.41‐43 This strategy has fallen out of favor and is not recom‐
mended any longer.
Studies have shown that hypervolemic therapy did not prevent 
DCI when compared to euvolemia; in fact, hypervolemia may in‐
crease the risk pulmonary edema, myocardial ischemia, and cerebral 
edema.44 In a randomized trial, prophylactic hypervolemia caused 
an overall fourfold increase in the risk of adverse events.45 The 
current guidelines have shifted toward a more euvolemic approach 
with main goal of avoiding hypovolemia without volume overload; 
prophylactic hypervolemia before the development of angiographic 
vasospasm is not recommended.5
Hemodilution is thought to increase global CBF by decreasing 
blood viscosity. However, it results in reduced oxygen delivery ca‐
pacity and may not increase the overall cerebral oxygen delivery.46 
It has mostly fallen out of favor as a current treatment modality for 
vasospasm. In spite of widespread early adoption, primarily based on 
retrospective studies, systematic reviews of “triple‐H” therapy for 
prophylaxis of vasospasm concluded that it does not appear to be 
beneficial for the prevention of vasospasm.42,47
Some components of this regimen are still currently in practice 
for treatment of symptomatic vasospasm, but not typically employed 
as a prophylactic measure for all patients. The induced hypertension 
component of “triple‐H” therapy is more effective in increasing CBF 
than hypervolemia and hemodilution. The loss of innate autoregula‐
tion during vasospasm makes cerebral perfusion pressure even more 
dependent on systemic blood pressure.48 This strategy is not used 
a preventive tool, but aims to reduce the risk of ischemia in patients 
developing vasospasm. Induced hypertension increases cerebral 
blood flow and brain tissue oxygenation, and may help in reversing 
neurological deficits. Induced hypertension relies on use of pressors, 
notably norepinephrine, dopamine, and phenylephrine, all of which 
have been shown to be successful in improving CBF and neurological 
outcome.49
3.6.2 | Nimodipine
Nimodipine is a calcium channel blocker originally used for blood 
pressure management. It crosses the blood‐brain barrier and causes 
vasodilation of vascular smooth muscle cells and thus is a main tool 
used in aSAH.
Nimodipine was initially studied in patients with aSAH as a 
means to prevent vasospasm. However, there is no convincing ev‐
idence that nimodipine affects the incidence of either angiographic 
or symptomatic vasospasm.50 But, nimodipine has been shown to 
improve neurological outcomes and to decrease mortality in pa‐
tients with aSAH and is part of the standard of care due to its neu‐
roprotective role.51,52
Per the AHA/ASA recommendations, oral nimodipine should 
be initiated as soon as possible, typically at a dose of 60 mg every 
4 hours, and maintained for about 21 days following SAH.5 The un‐
derlying mechanism for these effects is unclear, but it is known to 
be separated from its vasodilatory effects and could be related to 
resistance to calcium‐mediated excitotoxicity and a reduction in the 
formation of microthromboses, which play a role in development of 
vasospasm and DCI.36
Nimodipine is the only FDA‐approved drug to improve outcomes 
in aSAH. It has been reported to reduce the incidence of poor neuro‐
logical outcome by 40%.53 In a trial by Allen et al51 that included 125 
SAH patients, 1 of 56 patients who received nimodipine suffered 
from neurological deficit or death, which was statistically signifi‐
cant when compared to patients given a placebo (8 of 60 patients, 
P = .03). Several additional trials have confirmed the benefit of ni‐
modipine in reducing the incidence of DCI and improving outcomes 
in SAH. A meta‐analysis that analyzed the results of 16 trials evalu‐
ating the role of calcium channel blockers in aSAH, encompassing 
3361 patients, concluded that calcium channel blockers reduce the 
risk of poor outcome and secondary ischemia after aneurysmal SAH 
with oral nimodipine producing the most significant benefit and only 
with modest risks, systemic hypotension being the most common 
side effect of nimodipine.52
Other calcium channel blockers have been studied for treatment 
of vasospasm and DCI, most notably nicardipine, nitroprusside, and 
verapamil. There may be a role for the other calcium channel block‐
ers, but the benefit does not surpass that of nimodipine.52 In a trial 
on nicardipine that treated 449 patients with IV nicardipine vs 457 
patients with placebo, nicardipine‐treated patients had significantly 
reduced vasospasm compared to placebo (32% vs 46%, P < .001), but 
clinical outcomes were similar between the groups at 3 months.54
3.6.3 | Magnesium
Magnesium leads to vasodilatation of cerebral arteries by block‐
ing the voltage‐dependent calcium channels. Magnesium may 
TA B L E  2   Proposed mechanisms underlying cerebral vasospasm 
and DCI
Prolonged smooth muscle contraction from lysis of subarachnoid 
blood clots and blood degradation products
Endothelial damage and formation of microthrombosis
Decreased nitric oxide production leading to prolonged 
vasoconstriction
Increased production and release of the potent vasoconstrictor 
endothelin‐1
Cortical spreading depolarization increasing metabolic demand and 
decreasing blood supply
Inflammation‐mediated oxidative stress and free radical damage to 
smooth muscle cells
Upregulation of apoptosis pathways following aSAH
Abbreviations: aSAH, aneurysmal subarachnoid haemorrhage; DCI, 
delayed cerebral ischemia.
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TA B L E  3   Agents and interventions targeting vasospasm in aneurysmal subarachnoid hemorrhage
 Mechanism of action in vasospasm Use in clinical practice Comment
Hyperdynamic and 
“triple‐H” therapy
Increase the mean arterial pressure 
and increase cerebral perfusion
Hypervolemia and hemodilution 
have fallen out of practice.
Induced hypertension is utilized 
to reduce the risk of ischemia in 
patients who develop vasospasm 
but is not used as a prophylactic 
measure for all patients.
Systematic reviews concluded that “triple‐H” 
therapy does not appear to be beneficial for 
the prevention of vasospasm. Hypervolemia 
may increase the risk pulmonary edema, 
myocardial ischemia, and cerebral edema; 
maintaining euvolemia is recommended.
Nimodipine Calcium channel blocker causing 
vasodilatation of vascular smooth 
muscle cells.
Neuroprotective effect could be 
related to resistance to calcium‐
mediated excitotoxicity and a 
reduction in the formation of 
microthromboses
Oral nimodipine should be initiated 
as soon as possible after aSAH at a 
dose of 60 mg every 4 h and main‐
tained for about 21 d following SAH
No convincing evidence that nimodipine 
affects the incidence of either angiographic 
or symptomatic vasospasm
But, nimodipine has been shown to improve 
neurological outcomes and to decrease 
mortality in patients with aSAH and is part 





Other calcium channel blockers 
causing vasodilation of vascular 
smooth muscle cells.
Frequently utilized for blood pressure 
management in aSAH, especially nica‐
rdipine, but not routinely tailored for 
vasospasm prophylaxis and treatment
May reduce vasospasm but indeterminate 
effects on clinical outcomes. Benefit does 
not surpass that of nimodipine
Magnesium Vasodilatation by blocking volt‐
age‐dependent calcium channels. 
Magnesium may also block the 
release of glutamate, providing a 
potential neuroprotective benefit
Not routinely used in all patients 
with aSAH and has fallen out of 
standard practice given incon‐
sistent reports on its benefits. 
Correcting hypomagnesaemia is 
highly recommended.
Early animal studies and a phase II trial 
(MASH) reported positive results with 
intravenous magnesium.
IMASH and MASH‐2, two phase III trials, did 
not show significant clinical benefit
Milrinone Phosphodiesterase 3 inhibitor that 
leads to an increased level of intra‐
cellular cAMP causing vasodilata‐
tion. Potential antiinflammatory 
effects at the cerebral vessel wall.
Currently used in clinical practice 
occasionally in cases of refractory 
vasospasm not responsive to other 
measures and utilized intraarterially 
in patients who undergo endovas‐
cular interventions for symptomatic 
vasospasm.
Studies on intravenous and intraarterial 
milrinone have shown a safe profile and 
promising results in improving vasospasm. 
Overall role in improving patient outcomes 
still needs to be evaluated.
Statins Improve cerebral vasomotor reac‐
tivity by upregulating endothelial 
nitric oxide synthase and increas‐
ing nitric oxide biosynthesis.
May play a role in decreasing 
glutamate‐mediated excitotoxicity 
and help control the inflammatory 
response
Given the relative safety of statins, 
they are still used in clinical practice 
(pravastatin 40 mg daily or simvas‐
tatin 80 mg daily). The latest AHA/
ASA recommendations state that 
it is reasonable to administer statin 
therapy to patients after aSAH to 
prevent vasospasm despite lack of 
strong evidence of benefit. Therapy 
should be started early (within 48 h) 
and continued for 14‐21 d.
Positive early trial showing benefit on 
decreasing the incidence of vasospasm, 
but more recent studies have not reported 






Inhibit the binding of endothelin 1, 
a vasoconstrictive peptide that is 
overproduced in SAH
Not used in common practice due 
to prominent side effects (pulmo‐
nary edema, hypotension, cerebral 
infarction anemia, and hypotension)
Endothelin receptor antagonists may have a 
role in reducing vasospasm especially at a 
high dose with inconsistent effect on func‐
tional outcome and important side effects
Tirilazad Free radical scavenger and antioxi‐
dant effects, likely neuroprotec‐
tive role
Not currently used in standard 
practice
Studies have not proven a consistent clinical 
benefit.
A meta‐analysis involving 3821 patients 
found no significant difference with tirilazad 
compared with placebo with regard to death 
or poor outcome; fewer patients, however, 
developed DCI in the tirilazad group.
Fasudil Rho‐kinase inhibitor that acts a 
vasodilator
Fasudil is currently utilized in Japan 
for vasospasm prophylaxis. Because 
of the limited number of trials, it is 
not as widely endorsed elsewhere.
Several trials reported a reduced rate of 
angiographic and symptomatic vasospasm 
improved clinical outcomes. Large rand‐
omized, controlled clinical trials are needed 
to further establish the benefit.
(Continues)
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 Mechanism of action in vasospasm Use in clinical practice Comment
Cilostazol Platelet aggregation inhibitor 
may have a role in preventing 
microthrombi formation and has 
a vasodilatory effect by inhibiting 
phosphodiesterase 3 and increas‐
ing intracellular cAMP
Not used routinely Cilostazol seems to be a safe and promis‐
ing agent. One meta‐analysis showed a 
decreased risk of symptomatic vasospasm, 
cerebral infarction, and poor outcome. 
Further large multicenter trials are needed.
Albumin Neuroprotective properties likely 
related to its antioxidant and 
antiinflammatory properties. It 
increases oncotic pressure and 
reduces cerebral edema, increases 
neuronal survival, and maintains 
blood‐brain barrier integrity.
Used occasionally for volume 
resuscitation in SAH. Not routinely 
used for vasospasm prophylaxis or 
treatment.
ALISAH study identified that 1.25 g/kg/d of 
albumin is safe in patients with aSAH and 
may be associated with improved outcomes 
with no major complications. Further stud‐
ies are currently underway.
Eicosapentaenoic 
acid
Inhibits Rho‐kinase activation and 
smooth muscle contraction.
Not currently used in the clinical 
setting
Early reports showed positive results, and 
further studies are needed.
Heparin and low 
molecular weight 
heparin
Attenuates inflammatory response, 
this is different than its function in 
anticoagulation.
High‐dose heparin/low molecular 
weight heparin infusions are not 
currently recommended routinely 
given concern for hemorrhage. 
Low doses are used for prophylaxis 
against venous thromboembolism
Inconsistent results with concern for 
hemorrhage.
Erythropoietin neuroprotective properties through 
an indeterminate mechanism that 
seems to be unrelated to its func‐
tion in erythropoiesis
Not commonly used in practice The overall mechanisms and role in vasos‐
pasm are still unclear as well as the effect 
on clinical outcomes.
Corticosteroids Antiinflammatory properties Not commonly used in practice A randomized trial that administered 
high‐dose methylprednisolone (16 mg/kg) 
reported better functional outcome at one 
year. Further studies are needed.
Minocycline Antiinflammatory effects as well as 
serving as an iron chelator. Likely 
neuroprotective role.
Not commonly used in practice Multiple trials have evaluated minocycline in 
acute ischemic stroke and intracranial hem‐
orrhage patients with promising results and 
with a good safety profile. Role currently 
being evaluated in SAH.
Deferoxamine Iron chelator. May target iron and 
hemoglobin‐induced early brain 
injury
Not commonly used in practice Could be a promising agent; currently being 
evaluated in ICH and SAH and has reached 
clinical trials in ICH.
Intrathecal 
thrombolytics
Clearance of blood from the basal 
cisterns and ventricular system.
Not commonly used in practice A meta‐analysis showed an absolute risk re‐
duction in DCI, poor clinical outcome, and 
mortality. Intrathecal thrombolytics are 




Disruption of smooth muscle cells 
or extracellular matrix with result‐
ant dilatation of the vessel and 
increased cerebral blood flow
Commonly used in patients with 
symptomatic vasospasm not 
responding to other medical 
measures.
Not recommended for vasospasm 
prophylaxis.
Studies support this tool in the treatment of 
symptomatic vasospasm with improvement 
in vasospasm and patient outcomes. Large 
affirmative trials are missing, however.
Intraarterial 
papaverine
Increases cyclic AMP and causes 
vasodilatation
Not routinely used There are significant limitations with its use 
and prominent side effects. Its use is not 





Calcium channel blockers causing 
vasodilatation of vascular smooth 
muscle cells.
Commonly used in patients with 
symptomatic vasospasm especially 
when involving small distal vessels 
or as adjunct to transluminal bal‐
loon angioplasty
Randomized trials are still needed to 
establish effects on clinical outcomes 
and to compare the different intraarterial 
treatments.
Abbreviation: aSAH, aneurysmal subarachnoid hemorrhage.
TA B L E  3   (Continued)
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also block the release of glutamate, providing a potential neuro‐
protective benefit, and there is some suggestion of reduction in 
DCI associated with intravenous magnesium infusion.55,56 Based 
on these properties, magnesium has been historically utilized in 
patients with SAH and initiated frequently on presentation. This 
has somewhat fallen out of standard practice given inconsistent 
reports on its benefits.
Several clinical studies have evaluated the role of magnesium in 
patients with aSAH and its effect on cerebral vasospasm and neu‐
rological outcomes. Early animal studies and phase II data reported 
positive results with intravenous magnesium.56,57
The Magnesium in Aneurysmal Subarachnoid Hemorrhage 
(MASH) phase II trial randomized 283 patients to continuous IV 
magnesium infusion or placebo for 14 days after aneurysm treat‐
ment.56 Magnesium treatment reduced the risk of DCI by 34%, and 
at 3 months, the risk reduction for poor outcome was 23%. The 
study concluded that magnesium may reduce DCI and subsequent 
poor outcome.
However, there is a lack of level I evidence supporting routine 
use of IV magnesium for prophylaxis in patients with aSAH. In fact, 
several further well‐designed trials failed to show significant ben‐
efit in clinical outcomes in patients with aSAH who were treated 
with prophylactic magnesium infusion. The Intravenous Magnesium 
Sulphate for Aneurysmal Subarachnoid Hemorrhage (IMASH) 
trial,58 a randomized, double‐blinded, placebo‐controlled, mul‐
ticenter phase III trial, recruited 327 patients, 169 of whom were 
randomized to IV magnesium sulfate. Favorable clinical outcome 
was observed in 64% in the magnesium sulfate group and 63% in 
the placebo group (OR, 1.0; 95% CI, 0.7‐1.6). The Magnesium for 
Aneurysmal Subarachnoid Haemorrhage (MASH‐2),59 another ran‐
domized phase III placebo‐controlled trial, enrolled 1204 patients, 
606 receiving magnesium and 597 placebo, reported that 26.2% 
had poor outcome in the magnesium group compared with 25.3% in 
the placebo group (risk ratio [RR] 1.03, 95% CI 0.85‐1.25) and con‐
cluded that magnesium does not seem to improve clinical outcome 
in patients with aSAH. A meta‐analysis of seven randomized trials 
that included 2047 patients showed that IV magnesium does not 
reduce poor outcome after aSAH (RR 0.96, 95% CI 0.84‐1.10).59 The 
negative results could be related to magnesium's poor penetration 
in the CSF.58
Hypomagnesemia occurs in a large proportion of patients with 
SAH and could lead to worse outcomes.60 While maintaining mag‐
nesium within normal limits in patients with aSAH is reasonable, the 
current evidence does not support routine prophylactic and aggres‐
sive therapy in patients with aSAH. Furthermore, side effects asso‐
ciated with intravenous magnesium may offset any potential benefit 
(eg, hypocalcemia, hypotension).
3.6.4 | Milrinone
Milrinone is a phosphodiesterase 3 inhibitor. It leads to an increased 
level of intracellular cAMP causing vasodilation. In addition, mil‐
rinone also has potential antiinflammatory effects at the cerebral 
vessel wall. Milrinone's antiinflammatory effects may inhibit the ab‐
normal proliferation of vascular smooth muscle and the remodeling 
process observed in patients with DCI.61
There have been some reports and case series showing that 
high‐dose IV milrinone therapy (0.1‐0.2 mg/kg intravenous bolus, 
then 0.75‐1.25 mcg/kg/min) for symptomatic vasospasm and DCI 
can lead to angiographic and neurological improvement.62
In the Montreal Neurological Hospital protocol study, 88 pa‐
tients with aSAH received intravenous milrinone infusion with no 
significant side effects. About 75% of patients had a good functional 
outcome (modified Rankin scale ≤ 2). Systemic hypotension and 
tachycardia are notable side effects.
Overall, studies on milrinone have shown a safe profile and 
promising results, but it is still unclear to what degree it affects neu‐
rological outcome after aSAH.63‐65 Milrinone can be administered 
intraarterially with good results.65 A study by Fraticelli et al64 that 
included 34 intraarterial infusions of milrinone reported significant 
improvement in angiographic vasospasm (P<.0001). In addition, a 
combination of IA and IV milrinone therapy can be attempted.66
Milrinone is currently used in clinical practice occasionally in 
cases of refractory vasospasm not responsive to other measures 
and utilized occasionally intraarterially in patients who undergo 
endovascular interventions for symptomatic vasospasm. Further 
prospective randomized studies are needed to prove the improved 
outcomes with milrinone.
3.6.5 | Statins
Statins are HMG‐CoA reductase inhibitors thought to have the po‐
tential to improve cerebral vasomotor reactivity by upregulating 
endothelial nitric oxide synthase and increasing nitric oxide biosyn‐
thesis.67 This can increase cerebral blood flow and could play a role 
in prevention and treatment of vasospasm and DCI. Additionally, 
statins may play a role in decreasing glutamate‐mediated excitotox‐
icity and help control the inflammatory response in vasospasm.68
There have been some positive trials evaluating the role of statin 
treatment in aSAH.69‐72
A phase II placebo‐controlled trial randomized 80 patients with 
aSAH to either 40 mg of daily oral pravastatin or placebo for up to 
14 days. In patients treated with pravastatin, vasospasm and severe 
vasospasm were decreased by 32% (P = .006) and 42% (P = .044), 
respectively, in pravastatin‐treated patients. Pravastatin also de‐
creased the incidence of vasospasm‐DCI by 83% (P < .001) and mor‐
tality by 75% (P = .037).72
However, more recent trials have not replicated those re‐
sults.68,73,74 The simvastatin in aneurysmal subarachnoid haem‐
orrhage (STASH) trial,68 a multicentre randomized phase 3 trial, 
randomly assigned 391 patients to receive simvastatin 40 mg and 
412 patients to receive placebo. Favorable clinical outcome (mRS 
0‐2) was not statistically different between the two groups (OR of 
0.97, P = .803). The trial did not detect any overall benefit in the use 
of simvastatin and recommended against routine use of statins early 
in aSAH.
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Given the relative safety of statins, they are still used in clinical 
practice (pravastatin 40 mg daily or simvastatin 80 mg daily). The 
latest AHA/ASA recommendation published in 2012 states that it 
is reasonable to administer statin therapy to patients after aSAH 
to prevent vasospasm despite the lack of strong evidence of bene‐
fit.5 If statins were to be initiated, therapy should be started early 
(within 48 hours) and continued for 14‐21 days. Hepatotoxicity 
and rhabdomyolysis are rare complications of statins but have 
not been prominent in most trials despite the high‐dose regimens 
used. More definitive trials may still be needed to confirm the ef‐
fect of statins on outcomes, vasospasm, and DCI in aSAH given 
current mixed findings in the literature.
3.6.6 | Endothelin receptor antagonists
Endothelin receptor antagonists inhibit the binding of endothelin 1, 
a vasoconstrictive peptide that affects vascular smooth muscle con‐
traction. Endothelin is overproduced in SAH and is linked to devel‐
opment of vasospasm.75 Clazosentan is the most commonly studied 
endothelin receptor antagonist in SAH.
CONSCIOUS‐1, a phase II trial that randomized 413 patients 
to clazosentan or placebo, reported dose‐dependent reductions in 
angiographic vasospasm.76 Three different doses were used (1, 5, 
or 15 mg/h). Patients who received all three dosages had a statis‐
tically significant reduction in moderate and severe angiographic 
vasospasm as compared to placebo, with the 15 mg/h dosage hav‐
ing the greatest benefit (65% relative risk reduction in angiographic 
vasospasm). These results led to CONSCIOUS‐2, a prospective, dou‐
ble‐blinded, placebo‐controlled, phase III trial that enrolled 1157 
patients.77
A total of 728 patients received IV clazosentan (5 mg/h) and 389 
patients received placebo. The group receiving clazosentan did not 
have statistically significant improvement in clinical outcomes.
All‐cause mortality, vasospasm‐related infarcts, DCI, and rescue 
therapy for vasospasm occurred less frequently in the clazosentan 
group (21%) compared to the placebo group (25%); however, this dif‐
ference was not significant (P = .1).
Furthermore, this trial highlighted many side effects that in‐
cluded pulmonary edema, hypotension, pleural effusion, and ce‐
rebral infarction that required stopping the drug. Based on these 
findings, the CONSCIOUS‐3 trial that was recruiting patients was 
stopped early, enrolling 577 patients.78 Results were comparable 
for the 5 mg/h clazosentan dose. Clazosentan at 15 mg/h decreased 
the occurrence of vasospasm‐related morbidity, but did not improve 
functional outcomes (P = .266). Pulmonary complications, anemia, 
and hypotension were more common in patients who received 
clazosentan. This is also further demonstrated in meta‐analyses.79,80
A meta‐analysis that included 2159 patients using different 
doses of clazosentan (1‐15 mg/h) demonstrated that high‐dose 
treatment (15 mg/h) is associated with reduced incidence of va‐
sospasm and DCI at the expense of hypotension, pulmonary com‐
plications, and anemia, and no overall difference was observed 
in clinical outcomes.79 TAK‐044 is another endothelin receptor 
antagonist that has been studied less extensively but seems to 
have a similar profile to clazosentan. In one study, 207 patients 
were randomized to IV TAK‐044 and 213 to placebo. A trend to‐
ward decreased DCI was reported; however, there was no benefit 
in clinical outcomes at 3 months.81
Endothelin receptor antagonists may have some role in reducing 
vasospasm at a high dose, but reports on overall clinical benefit have 
been inconstant and the common side effects have pushed these 
medications out of standard practice.
3.6.7 | Tirilazad
Tirilazad functions as a free radical scavenger. This antioxidant effect 
is believed to confer a neuroprotective benefit in aSAH.82,83 A trial 
that enrolled 1015 patients randomized to receive tirilazad at 6 mg/
kg/day demonstrated significantly reduced overall mortality (P < .01) 
and improved clinical outcomes at 3 months compared to patients 
who received placebo (P < .01).84 The benefits of treatment with tirila‐
zad were predominantly shown in men rather than in women.
The North American multicenter cooperative tirilazad trial 
studied 897 patients who received 6 mg/kg per day tirilazad or pla‐
cebo.85 At 3 months post‐SAH, there were no significant differences 
in mortality, clinical outcome, or employment status. During the first 
14 days after the SAH, there were no significant differences in the 
incidence or severity of clinical or angiographic cerebral vasospasm.
A meta‐analysis that included five double‐blind, placebo‐con‐
trolled trials involving 3821 patients found no significant difference 
in patients treated with tirilazad started within four days of SAH 
onset, compared with placebo with regard to death or poor out‐
come; fewer patients, however, developed DCI in the tirilazad group 
(OR 0.80, 95% CI 0.69‐0.93).82
Tirilazad studies have not proven a consistent clinical benefit fol‐
lowing aSAH. This medication is not currently utilized in standard 
practice.
3.6.8 | Fasudil
Fasudil is a Rho‐kinase inhibitor that acts as a vasodilator. Rho‐kinase 
is thought to play a role in the mechanisms dictating vasoconstric‐
tion, endothelial injury, inflammation, and production of reactive 
oxygen species.86
In a trial by Shibuya et al87 that randomized 131 patients to 
receive IV fasudil for 14 days and 136 patients to placebo, fasudil 
reduced angiographic vasospasm by 38% from 61% in the placebo 
group (P = .0023) and symptomatic vasospasm by 30% (P = .0247) 
and significantly improved clinical outcomes according to the one‐
month GOS scores (P = .0152). In a randomized clinical trial, the use 
of fasudil 30 mg as a daily IV bolus was compared with IV nimodip‐
ine.86 Neither the incidence of clinical vasospasm nor the occurrence 
of CT hypodensities differed significantly between the two groups. 
However, the clinical outcomes were more favorable in the fasudil 
group than in the nimodipine group (74.5% vs 61.7%, P = .040). 
There were no serious adverse events reported with fasudil. In this 
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study, however, the nimodipine group received approximately half of 
the recommended treatment dose.
A meta‐analysis by Liu et al88 reported that fasudil significantly 
reduced the occurrence of vasospasm and DCI in SAH patients, and 
improved clinical outcomes.
Fasudil has been primarily studied in Japan and is currently uti‐
lized in Japan for vasospasm prophylaxis.89 Because of the limited 
number of trials, it is not as popular elsewhere. Large randomized, 
controlled clinical trials are needed to further establish the benefit 
of fasudil in aSAH.
3.6.9 | Cilostazol
Cilostazol is a platelet aggregation inhibitor. It may have a role in 
preventing microthrombus formation that is cytotoxic and may con‐
tribute to cerebral vasospasm. Cilostazol has a vasodilatory effect 
on the cerebral arteries as well through its inhibitory effect on phos‐
phodiesterase 3 increasing intracellular concentrations of cAMP.90
In one multicenter prospective, randomized trial, 54 patients 
with aSAH were randomized to cilostazol treatment and 55 pa‐
tients to placebo. Symptomatic vasospasm occurred in 13% of the 
cilostazol group vs 40% in the placebo group (P = .0021). The inci‐
dence of angiographic vasospasm was also significantly lower in the 
cilostazol group (P = .0055). No significant difference was found in 
clinical outcomes.91
In a meta‐analysis by Saber et al,92 comparing 271 patients with 
aSAH treated with cilostazol and 272 with placebo, cilostazol was as‐
sociated with a decreased risk of symptomatic vasospasm (P < .001), 
cerebral infarction (P < .001), and poor outcome (P < .001). 
Cilostazol seems to be a safe and promising agent, and further 
large multicenter trials are needed before it gets widely adopted in 
clinical practice.
3.6.10 | Albumin
Human albumin is thought to have neuroprotective properties likely 
related to its antioxidant and antiinflammatory properties.93,94 It has 
been shown to increase serum oncotic pressure and reduce cerebral 
edema, increase neuronal survival, and maintain blood‐brain barrier 
integrity.95,96 The Albumin in Subarachnoid Hemorrhage (ALISAH) 
pilot study included 47 patients and identified that 1.25 g/kg/d of 
albumin is safe in patients with aSAH and may be associated with 
positive outcomes.93 There were no major complications. A second‐
ary analysis showed that higher dosages of albumin were associated 
with a lower incidence of vasospasm, DCI, and cerebral infarction 
at 90 days, in a dose‐dependent fashion.97 Further studies are cur‐
rently underway to further evaluate the role of albumin in the man‐
agement of aSAH and cerebral vasospasm.
3.6.11 | Eicosapentaenoic acid
The sphingosylphosphorylcholine‐Rho‐kinase pathway plays an im‐
portant role in vascular smooth muscle contraction. Eicosapentaenoic 
acid is an omega‐3 polyunsaturated fatty acid that inhibits this pro‐
cess and has been shown to inhibit the occurrence of cerebral vasos‐
pasm in animal models.98‐100
A prospective multicenter randomized trial randomized 162 
patients with SAH postaneurysm clipping to 900 mg of eicosapen‐
taenoic acid three times daily for 30 days or no trial drug. The occur‐
rence of symptomatic vasospasm (15% vs 30%, P = .02) and cerebral 
infarction vasospasm (7% vs 21%; P = .01) was lower in the treatment 
group.
Eicosapentaenoic acid is not currently used in the clinical set‐
ting, but early reports showed positive results and further studies 
are needed.
3.6.12 | Heparin and low molecular weight heparin
Heparin and low molecular weight heparin infusions have been eval‐
uated in aSAH with inconsistent results.101‐103 Heparin has antiin‐
flammatory properties different than its role in anticoagulation. It is 
thought to attenuate the inflammatory response and restore blood‐
brain barrier integrity.104 Wurm et al102 reported a significant re‐
duction in vasospasm and DCI and improvement in 1‐month clinical 
outcomes in patients treated with enoxaparin vs placebo, whereas a 
study by Siironen et al103 reported no effect of enoxaparin on out‐
comes in aSAH and reported a slight increase in intracranial hem‐
orrhage. The use of anticoagulation is not currently recommended 
routinely, outside the standard injections for prophylaxis against 
venous thromboembolism.
3.6.13 | Erythropoietin
Erythropoietin is a hormone produced primarily by the kidneys and 
plays an essential role in the production of red blood cells. In animal 
studies, erythropoietin has been shown to have some neuroprotec‐
tive properties through an indeterminate mechanism that seems to 
be unrelated to its function in erythropoiesis.105‐108 It has been re‐
ported to reduce the severity of vasospasm. A phase II randomized 
trial that included 80 patients who received 30 000 U of intravenous 
erythropoietin or placebo every 48 hours for a total of 90 000 U 
showed a decreased incidence of severe vasospasm from 27.5% to 
7.5% (P = .037), reduced DCI from 40% to 7.5% (P = .001), and bet‐
ter outcome at discharge (P = .039).109 In a study on seven patients 
with SAH and cerebral vasospasm, 30 000 IU of erythropoietin was 
injected for 3 days. This resulted in an increase in brain tissue oxygen 
tension significantly over baseline.107 The overall mechanisms and 
role in vasospasm are still unclear as well as the effect on clinical 
outcomes.
3.6.14 | Corticosteroids
The role of inflammation is central to the development of vasospasm 
and early brain injury post‐SAH. Corticosteroids that interfere with 
the glucocorticoid receptor are able to downregulate this inflam‐
matory response. A randomized trial that administered high‐dose 
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methylprednisolone (16 mg/kg) to patients with aSAH reported 
better functional outcome at one year when compared to control 
patients (poor outcome of 15% in the treatment group vs 34% in 
controls, CI 95% CI 0.5%‐37.9%).110 The use of corticosteroids in 
aSAH warrants further investigation.
3.6.15 | Minocycline
Matrix metalloproteinase (MMP) is strongly involved in the patho‐
physiology of blood‐brain barrier disruption and CNS injury.111‐113 
MMP‐9 levels are increased following SAH, and several studies 
have suggested a role for MMP‐9 in early brain injury after SAH 
and correlation between MMP‐9 levels and vasospasm in animal 
models.114‐119
Fischer et al120 evaluated blood samples in 20 patients with aSAH 
and showed that MMP‐9 was higher in aSAH patients compared to 
healthy controls (P < .001) and an increase in MMP correlated with 
occurrence of vasospasm (P < .05).
Minocycline is a lipophilic semisynthetic second‐generation tet‐
racycline antibiotic that is a broad MMP inhibitor, with a good safety 
profile, used for other indications in humans. It has antiinflammatory 
effects in addition to serving as an iron chelator; thus, it has the po‐
tential of mitigating early brain injury following aSAH.121
Multiple trials have evaluated the neuroprotective role of mi‐
nocycline in acute ischemic stroke and intracranial hemorrhage pa‐
tients. A review by Malhotra et al122 evaluated 426 patients with 
ischemic or hemorrhagic stroke and reported that minocycline 
demonstrated a trend toward favorable functional outcome (P = .06) 
with a significant improvement in outcomes in the acute ischemic 
stroke subgroup (RR = 1.59, P = .002). Chang et al123 administered 
10 mg/kg of minocycline over 2 hours on a daily basis for 5 days 
post‐ICH. They demonstrated no harmful effects and a reduction in 
MMP 9 levels. With minocycline's potential neuroprotective effects, 
positive research in stroke and intracerebral hemorrhage and with 
its excellent safety profile, a clinical trial in aSAH patients may be 
warranted.
3.6.16 | Deferoxamine
The amount of blood released during aSAH has been shown to be 
related to the degree of neurological injury and poor outcome.124 
Abnormally high levels of iron in the brain can lead to significant 
oxidative damage via free radical production.125‐127 Recent studies 
showed that oxidative injury and iron overload play a significant role 
in brain damage after intracerebral hemorrhage.126,127 Iron deposi‐
tion after intracranial hemorrhage seems to be related to oxidative 
injury, resulting in brain edema, neuronal cell death, and delayed 
brain atrophy and secondary brain injury.128‐130
Deferoxamine is an iron chelator that chelates the unbound iron 
responsible for catalyzing the production of reactive oxygen species 
and blocks neurotoxic effects of hemoglobin.131 Previous studies 
found that deferoxamine reduces hemoglobin‐induced brain edema 
and decreases brain injury in experimental ICH.130,131
Deferoxamine has currently reached clinical trials for ICH. 
The Deferoxamine Mesylate in Patients with Intracerebral 
Haemorrhage (i‐DEF) phase 2 trial132 evaluated clinical outcomes 
after deferoxamine treatment and showed promising results after 
180 days (mRS 0‐2 of 45.2% in the deferoxamine group vs 35.6% 
in the placebo group), although the trial did not meet the pri‐
mary outcomes at 90 days. Clinical outcome differences in favor 
of deferoxamine exceeded the prespecified futility threshold at 
180 days which was not met at 90 days, showing future need to 
explore deferoxamine.
In a rodent SAH model study, deferoxamine treatment reduced 
SAH‐induced mortality (12% vs 29%, P < .05), brain nonheme iron 
concentration, iron‐handling protein expression, oxidative stress, 
and neuronal cell death at day 3 (P < .01).125
In another rodent study, deferoxamine injection resulted in a 
significant increase in hypoxia‐inducible factor (HIF)‐1 (a transcrip‐
tion factor that regulates the expression of various neuroprotective 
genes) in the brainstems of rats with aSAH. This resulted in a sig‐
nificant decrease in rate of cerebral vasospasm.133 Deferoxamine is 
rapidly absorbed and easily penetrates the blood barrier. Increased 
iron deposition after SAH and hemoglobin degradation may be a 
therapeutic target for patients with aSAH, and future clinical trials 
are needed to further establish the role of deferoxamine and iron 
chelators in the treatment of aSAH.
3.6.17 | Intrathecal and intraventricular therapy
The major advantage of delivery of treatment through an intrathecal 
or intraventricular route is the ability to achieve higher drug con‐
centrations directly around the area of vasospasm and minimizing 
systemic toxicity.
Nicardipine is a calcium channel blocker used for treatment 
of hypertension, commonly utilized in its intravenous form. 
Intraventricular nicardipine in aSAH has been studied in small case 
series.134,135 A retrospective study by Goodson et al134 reviewed 
eight patients with aSAH with refractory vasospasm who re‐
ceived intraventricular nicardipine 4 mg every 12 hours for a total 
of 5‐17 days. The study reported that seven of eight patients had 
moderate‐to‐good outcomes. In a case‐control study by Lu et al135 
(14 patients who received the treatment and 14 matched aSAH pa‐
tients), intraventricular nicardipine administration decreased mean 
flow velocity in the middle cerebral arteries, but there was no sig‐
nificant difference in outcomes. These studies reported minimal 
side effects. A phase II prospective, randomized trial evaluated the 
insertion of nicardipine‐releasing implants at the time of surgery. 
Thirty‐two patients were included. Nicardipine was more effective 
than placebo in decreasing the incidence of vasospasm (7% vs 73%; 
P < .05) and DCI (14% vs 47%; P < .05).136
Intraventricular nimodipine is currently being studied as well 
with the goal to maximize the benefit of this agent while reducing 
toxicity. The NEWTON trial defined 800 mg as a safe and tolerable 
intraventricular dose.137 NEWTON 2, a phase III randomized clinical 
trial, is currently underway.138
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Intraventricular milrinone and sodium nitroprusside have been 
evaluated as well in small studies.139,140
In addition, studies have investigated the administration of in‐
trathecal thrombolytics in aSAH to help with the clearance of blood 
from the basal cisterns and ventricular system. One trial randomized 
49 patients to placebo and 51 patients to intracisternal tPA at the 
time of aneurysm clipping. The incidence of angiographic vasospasm 
between the seventh and eleventh day following SAH was similar 
between the two groups (74.4% in the placebo group vs 64.6% in the 
rtPA group), with a trend toward a lower rate of vasospasm in the tPA 
group. Furthermore, the group that received tPA with a thick sub‐
arachnoid clot had a 56% relative risk reduction of severe vasospasm 
compared to placebo (P < .02).141 Hamada et al142 randomized 57 pa‐
tients to intrathecal urokinase and 53 patients to no thrombolytics 
following aneurysm coiling. Patients in the treatment group expe‐
rienced a significant reduction in symptomatic vasospasm (8.8% vs 
30.2%, P < .012) and improvement in clinical outcomes at 6 months 
(P = .036) without side effects.
A meta‐analysis that included 652 patients reported positive 
results with an absolute risk reduction in DCI of 14.4% (P < .001), 
in poor clinical outcome of 9.5% (P < .01), and in death of 4.5% 
(P < .05).143
Intrathecal/intraventricular administration of these various 
agents cannot be currently recommended as level I evidence is 
lacking to support the routine use of locally administered therapy. 
Further prospective randomized trials evaluating safety and efficacy 
are required.
3.6.18 | Intraarterial treatment and angioplasty
Symptomatic cerebral vasospasm refractory to medical treatment 
and DCI requires further interventions. Mechanical dilation using 
percutaneous transluminal balloon angioplasty has become the 
mainstay of treatment for symptomatic focal vasospasm of the 
larger cerebral arteries that is refractory to medical treatment.5
The suggested mechanism of this approach is related to disrup‐
tion of smooth muscle cells or extracellular matrix with resultant dil‐
atation of the vessel and increased cerebral blood flow.144
In 1984, Zubkov et al145 reported the first use of transluminal 
balloon angioplasty for cerebral vasospasm after aSAH with good 
results. 
Angioplasty has high success rates in proximal arteries including 
the internal carotid and vertebral arteries.146‐148 In a review by Hoh 
and Ogilvy, angioplasty resulted in clinical improvement in 62% of 
patients, significantly improved mean TCD velocities (P < .05), sig‐
nificantly improved cerebral blood flow in 85% of patients, and was 
associated with a 5% complication rate.149 One report identified that 
institutions that use interventional modalities such as balloon angio‐
plasty for vasospasm had a 16% reduction in risk of in‐hospital death 
(RR, 0.84, P = .03).150 In clinical practice, and despite strong level I 
evidence, transluminal balloon angioplasty is often pursued in pa‐
tients with severe vasospasm and symptoms refractory to medical 
treatment.
Prophylactic use of angioplasty, however, is not recommended. 
One multicenter randomized trial that included 170 patients with the 
Fisher grade III SAH randomized 85 patients to prophylactic angio‐
plasty. The study did not show benefit in clinical outcomes from pro‐
phylactic intervention and showed a procedure‐related complication 
rate of 5%.151 Per the current AHA/ASA recommendations, balloon 
angioplasty before the development of angiographic vasospasm is 
not recommended but is reasonable in patients with symptomatic 
vasospasm, particularly those who are not rapidly responding to hy‐
pertensive therapy.5
Chemical angioplasty consisting of intraarterial administration of 
vasodilators is also an option that is generally used for diffuse vaso‐
spasm involving smaller arterial branches. Intraarterial nicardipine, 
papaverine, milrinone, nimodipine, and verapamil have been utilized 
in treatment of symptomatic vasospasm.152‐156
Intraarterial papaverine causes vasodilatation, likely related 
to alteration in cAMP. It can result in transient reversal of cere‐
bral hypoperfusion with improvement in blood flow velocities and 
CBF.83,157,158 There are significant limitations with its use. It has a 
short‐lived effect, and patients may require multiple treatments. It 
also has some neurotoxic effects and may result in increased intra‐
cranial pressure, brainstem depression seizures, altered mental sta‐
tus, and hypotension.
Given these limitations, papaverine is not routinely recom‐
mended for the treatment of vasospasm and its use is limited in 
aSAH.
The primary limitation of vasodilator therapy is related to the 
shorter duration of benefit and an increased incidence of recurrent 
vasospasm. Intraarterial verapamil, nicardipine, nimodipine, and mil‐
rinone appear to be safer than papaverine and provide a more dura‐
ble response. Most of these agents have been tested in case series 
and have become widely adopted in clinical practice despite lack of 
strong established evidence. Randomized trials are still needed to 
establish safety and efficacy and to compare the different intraar‐
terial treatments.
3.7 | Animal models of SAH
Animal models are essential to the study of SAH and its effects. 
There are numerous studied animal models of SAH.159 Some involve 
the puncture or perforation of a cerebral vessel involving the use 
of a needle or catheter, or via a suture tied around the vessel.160 
Endovascular approaches have also been utilized using intraluminal 
filaments advanced into a cerebral vessel with subsequent puncture.
Other models use injection of blood into a cistern. The cisterna 
magna is the most common site for blood injection in animal models. 
Blood may be introduced into the cisterna magna via a microcatheter 
or by direct puncture.161 Models of SAH in the anterior circulation 
have also been developed using injection of blood into the perichi‐
asmatic cistern.162 In addition, there are single and double injection 
models.
Direct injection of blood is often the preferred method, given 
the ability of the investigator to control the initiation, volume, and 
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rate of hemorrhage, into the cisterna magna or the prechiasmatic 
cistern.163
Originally, large animal models of SAH such as dogs and primates 
were used. In particular, primates were the preferred model because 
of similarities in their brain structure to humans. The first animal 
model of SAH that was developed was in primates.164 The basilar ar‐
tery was exposed by craniotomy, and autologous blood was injected 
into the subarachnoid space surrounding it. However, high cost and 
the small number of animals that can be tested have limited this use 
of this model.
Canine models represent a popular model to study SAH given 
the large size of the animal and relatively lower cost than primates. 
More recently, the rat model has become one of the most utilized 
animal models of SAH due to low cost and ability to use large num‐
bers of animals.165 Other model species studied in SAH include mice, 
rabbits, cats, and pigs.
Although many therapeutic agents were met with great suc‐
cess in preclinical animal studies, the failure in translation of these 
findings into clinical trials could be related to a wide variability in 
animal models and lack of standardized methodology. Some of the 
variables include volume of blood injected, the method of injection, 
with or without withdrawal of CSF, injection times, the use of sin‐
gle vs double injection models, and vascular perforation techniques. 
More recently, there has been an increase in acute SAH models fo‐
cusing on early brain injury given the increasing clinical interest in 
this entity.
To note, the recently described glial‐lymphatic or glymphatic 
pathway, a fluid clearance pathway that subserves the flow of CSF 
into the brain along arterial perivascular spaces, has been found to 
be impaired in SAH.166 There appears to be impaired CSF inflow 
starting at 24 hours after the insult attributed to the occlusion of 
perivascular spaces by blood components.167 This could represent 
another target that warrants investigation in animal models of SAH.
4  | CONCLUSION
Available treatments for aSAH continue to expand. Vasospasm and 
resultant DCI continue to be a significant cause of morbidity and mor‐
tality after SAH. No single‐treatment algorithm has shown to be uni‐
formly effective in preventing post‐aSAH complications. Vasospasm 
after aSAH appears to be a multifactorial process, and the etiology 
of cerebral vasospasm remains incompletely understood.
Oral nimodipine continues to be the primary medication rou‐
tinely used in practice given its neuroprotective properties and 
data supporting improvement in clinical outcomes. There have 
been many studies evaluating the role of other medical and in‐
terventional treatments for aSAH and particularly vasospasm pre‐
vention and treatment. Many of these treatments have crossed 
into clinical practice. There is growing evidence supporting that 
early brain injury in aSAH may be related to significant morbid‐
ity and mortality. This needs to be explored further. Many of 
the current experimental drugs may have significant roles in the 
treatment algorithm of aSAH, early brain injury, and vasospasm 
and further trials are needed.
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